Arhaus saw an 84% year-on-year increase in web traffic in September, with third-quarter traffic up over 60%, outperforming peers significantly. Jefferies raised its EBITDA forecast for Q4 by about 2% and its 2027 EBITDA estimate by over 6% above analyst consensus, setting a $12 price target implying nearly 20% upside. The growth is attributed to a larger mailing list and increased digital marketing, with expectations for further gains from the incoming chief digital officer. This strong digital engagement and earnings outlook highlight Arhaus's premium position in the market.
Arhaus's web traffic surged 84% year-on-year in September, signaling strong digital engagement ahead of its raised EBITDA forecasts. For readers following the Consumer Cyclical sector, here is Pluang's market snapshot as of Oct 07, 2026 01:21 WIB: out of 112 priced US stocks, 73 rose and 39 fell. Notable movers include Tripadvisor Inc (TRIP) at USD 8.46 with 0% Sell / 100% Buy order activity, Autozone Inc (AZO) at USD 2,908.25 with 90% Sell / 10% Buy, and Carnival Corp (CCL) at USD 26.46 with 95% Sell / 5% Buy order activity.
Neogen reported earnings per share of $0.08 and revenue of $222.8 million, both exceeding analyst expectations. The company also announced a strategic partnership with Hinalea Imaging Corp. to develop digital food safety tools. However, Neogen's stoc...
PepsiCo is set to report its Q3 2026 earnings with expectations of $2.29 EPS and $25 billion revenue. The company faces challenges in North America, where organic revenue declined due to pricing pressures and changing consumer preferences. To adapt, ...
Stryker experienced an 8.8% stock drop on September 8, 2026, wiping out over $10 billion in market value due to ongoing manufacturing problems that were thought resolved. Truist Financial lowered its price target from $340 to $310, reflecting concern...
Bank OZK is scheduled to release its Q3 2026 earnings after market close on October 20, providing investors with updated financial results to compare against Citigroup's current Sell rating. The bank's latest balance sheet shows $41.70 billion in tot...
Scotiabank has increased its price target for Pfizer stock from $30.00 to $33.00, suggesting a potential upside of 20.9% from the current trading price of $27.31. Pfizer, a major pharmaceutical company, holds a strong buy rating with a Zacks Rank of ...
